Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control

Sci Rep. 2023 Oct 6;13(1):16843. doi: 10.1038/s41598-023-42299-4.

Abstract

Combining viruses and nanoparticles may be a way to successfully treat cancer and minimize adverse effects. The current work aimed to evaluate the efficacy of a specific combination of gold nanoparticles (GNPs) and Newcastle disease virus (NDV) to enhance the antitumor effect of breast cancer in both in vitro and in vivo models. Two human breast cancer cell lines (MCF-7 and AMJ-13) and a normal epithelial cell line (HBL-100) were used and treated with NDV and/or GNPs. The MTT assay was used to study the anticancer potentials of NDV and GNP. The colony formation assay and apoptosis markers were used to confirm the killing mechanisms of NDV and GNP against breast cancer cell lines. p53 and caspase-9 expression tested by the qRT-PCR technique. Our results showed that combination therapy had a significant killing effect against breast cancer cells. The findings demonstrated that NDV and GNPs induced apoptosis in cancer cells by activating caspase-9, the p53 protein, and other proteins related to apoptosis, which holds promise as a combination therapy for breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Breast Neoplasms* / therapy
  • Caspase 9 / genetics
  • Cell Line, Tumor
  • Female
  • Gold
  • Humans
  • Immunotherapy
  • Metal Nanoparticles*
  • Newcastle disease virus
  • Oncolytic Virotherapy* / methods
  • Oncolytic Viruses*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Caspase 9
  • Gold
  • Tumor Suppressor Protein p53